Ospedale Niguarda Ca' Granda, best known simply as Ospedale Niguarda or Niguarda Hospital is largest and one of the most important hospitals in Milan, Italy.

During the past decade, ASST Grande Ospedale Metropolitano Niguarda conducted 233 clinical trials. In the 10-year time frame, 233 clinical trials started and 73 clinical trials were completed, i.e. on average, 31.3% percent of trials that started reached the finish line to date. In the past 5 years, 126 clinical trials started and 59 clinical trials were completed. i.e. 46.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ASST Grande Ospedale Metropolitano Niguarda" #1 sponsor was "Niguarda Hospital" with 24 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 17 trials sponsored, "Celgene" with 15 trials sponsored, "Janssen Research & Development, LLC" with 15 trials sponsored and "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 15 trials sponsored. Other sponsors include 245 different institutions and companies that sponsored additional 143 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ASST Grande Ospedale Metropolitano Niguarda" #1 collaborator was "Eli Lilly and Company" with 7 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "Istituto Di Ricerche Farmacologiche Mario Negri" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator and "Niguarda Hospital" with 4 trials as a collaborator. Other collaborators include 262 different institutions and companies that were collaborators in the rest 248 trials.

According to Clinical.Site data, the most researched conditions in "ASST Grande Ospedale Metropolitano Niguarda" are "Heart Failure" (14 trials), "Multiple Myeloma" (12 trials), "Metastatic Colorectal Cancer" (8 trials), "Leukemia, Myeloid, Acute" (7 trials) and "Myelodysplastic Syndromes" (7 trials). Many other conditions were trialed in "ASST Grande Ospedale Metropolitano Niguarda" in a lesser frequency.

Most popular intervention types in "ASST Grande Ospedale Metropolitano Niguarda" are "Drug" (225 trials), "Device" (39 trials), "Other" (34 trials), "Procedure" (20 trials) and "Biological" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (40 trials), "Rituximab" (11 trials), "Ibrutinib" (8 trials), "Carboplatin" (7 trials) and "Cisplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "ASST Grande Ospedale Metropolitano Niguarda" are 323 trials for "All" genders, 9 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 132 active trials in "ASST Grande Ospedale Metropolitano Niguarda". 2 are not yet recruiting, 79 are recruiting, 48 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 137 completed trials in ASST Grande Ospedale Metropolitano Niguarda, 1 suspended trials, and 29 terminated clinical trials to date.

Out of the total trials that were conducted in ASST Grande Ospedale Metropolitano Niguarda, 27 "Phase 1" clinical trials were conducted, 103 "Phase 2" clinical trials and 116 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 28 trials that are defined as “Not Applicable".

ASST Grande Ospedale Metropolitano Niguarda has several departments that took part in Clinical trials: "Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck" - 8 trials, "Divisione di Ematologia, Ospedale Niguarda" - 5 trials, "Asst Ospedale Metropolitano Niguarda - Cardiologia 1 - Emodinamica" - 3 trials, "Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze" - 3 trials, "Ospedale Niguarda, Cardiologia 1 - Emodinamica" - 2 trials, "Niguarda Cancer Center - ASST Grande Ospedale Metropolitano Niguarda" - 2 trials, "Ospedale Niguarda-Ca Granda, Dept. of Internal Medicine Padiglione Brera" - 2 trials, "ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Dipartimento di Nefrologia e Dialisi" - 2 trials